Le Lézard
Classified in: Health, Science and technology, Business
Subject: CXP

Northway Biotech Opens New Biopharmaceutical Manufacturing Facility in Greater Boston Area


WALTHAM, Mass., Jan. 20, 2021 /CNW/ -- Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art, cGMP manufacturing site in Europe, announced at the virtual grand opening ceremony on Jan. 20, 2021, the opening of its new 30,000-square-foot process development and cGMP manufacturing site in Waltham, Massachusetts.

From cell line development to cGMP DS manufacturing and aseptic filling, the state-of-the-art facility, in the booming biotech hub in the Greater Boston area, will provide end-to-end services for biologics microbial and mammalian based biologics. Currently, the new site has fully established process, analytical method development, and quality control labs supporting local and international customer projects since summer 2020. The cGMP biomanufacturing suite will house 500 L microbial and 2,000 L mammalian bioreactors and be operational in Q4 2021, representing a capital investment program worth $40 million.

"Northway Biotech reaches an important strategic milestone to further strengthen its leadership by opening a second biomanufacturing facility and its first in the United States. We are very excited about this expansion and are poised to support our next-door partners in the Boston biotech hub, as well as other domestically or internationally located companies, by enabling accelerated development and manufacturing of their novel, life-saving biopharmaceuticals for clinical or commercial needs," said Dr. Vladas Algirdas Bumelis, CEO of Northway Biotech and Executive Chairman of the company's Board of Directors and Advisory Board.

Earlier last month, the company announced that it is changing its brand name from Northway Biotechpharma to Northway Biotech to harmonize its brand name across EU and U.S.-located sites.

About Northway Biotech - https://www.northwaybiotech.com

Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania; London, United Kingdom; and Waltham, Massachusetts, United States. 

For Further Information, Contact: 

Dr. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com

Related Files

Northway Biotech opens new biopharmaceutical manufacturing facility in Greater Boston Area.pdf

Related Images

northway-biotech-opens-new.jpg
Northway Biotech opens new biopharmaceutical manufacturing facility in Greater Boston Area
Northway Biotech opens new biopharmaceutical manufacturing facility in Greater Boston Area

 

SOURCE Northway Biotech


These press releases may also interest you

at 03:22
Yiling Pharmaceutical's business income in 2020 hits 8.736 billion yuan (USD 1.35 billion) with an increase of 49.97% YoY, and the net profit reaches 1.220 billion yuan (USD 189 million), 101.12% YoY growth, according to the Annual Performance...

at 03:00
No one epitomizes the cool use of logic like Sherlock Holmes, who sliced through ignorance and ambiguity with his sharp, precise intellect. "Sentiment," he once remarked, "is a chemical defect found on the losing side." Emotions are often viewed as...

26 fév 2021
The LaunchPorttm announced today that Novel Microdevices (http://www.noveldx.com) has moved to their Medtech venture center in Port Covington, Baltimore, and has established The LaunchPorttm as its primary location for their GMP development efforts....

26 fév 2021
Nanalysis Scientific Corp. ("Nanalysis" or the "Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) is pleased to announce that the Board of Directors has granted 1,048,000 stock options to certain directors, officers, employees and consultants in...

26 fév 2021
ChenMed, a leading provider of primary care for underserved seniors, is pledging $100,000 in 2021 to address issues affecting communities of color. The philanthropic commitment is part of the company's continued efforts focused on cultural diversity,...

26 fév 2021
Following today's positive advisory committee meeting outcome regarding the Janssen Biotech Inc. COVID-19 Vaccine, the U.S. Food and Drug Administration has informed the sponsor that it will rapidly work toward finalization and issuance of an...



News published on 20 january 2021 at 23:05 and distributed by: